

Felvizumab

Cat. No.:	HY-P99615
CAS No.:	167747-20-8
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Felvizumab (SB 209763) is a humanized IgG1k monoclonal antibody directed to distinct neutralizing epitopes on the F glycoprotein of RSV ^{[1][2]} .	
IC₅₀ & Target	EC ₅₀ : 0.49 µg/mL (RSV Type A in microneutralization assay), 0.95 µg/mL (RSV Type A in fusion inhibition assay) ^[2]	
In Vitro	Felvizumab (RSHZ19) (2 h or 4 h) inhibits RSV Type A with an EC ₅₀ of 0.49 ± 0.37 µg/mL in microneutralization assay and with an EC ₅₀ of 0.95 ± 0.13 µg/mL in fusion inhibition assay ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Felvizumab (RSHZ19) (0.625-5.0 mg/kg; intramuscular injection; once) is effective against A and B subtypes of RSV in the cotton rat model of RSV infection ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Cotton rats, RSV infection model ^[2]
	Dosage:	0.625, 1.25, 2.5, and 5.0 mg/kg
	Administration:	Intramuscular injection, 1 day before infection
	Result:	Significantly reduced lung RSV titer.

REFERENCES

- [1]. Fenton C, et al. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection. *Paediatr Drugs*. 2004;6(3):177-97.
- [2]. Johnson S, et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. *J Infect Dis*. 1999 Jul;180(1):35-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA